Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19828807 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL15561335 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL7095353 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL7096279 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL905734 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL15561344 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL574387 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL5793190 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL6387083 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL2364491 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118340917-A | PET/MR bimodal imaging probe based on magnetic ferric oxide nanoparticle | 江南大学附属医院 | 2024-07-16 | — | — | CN | claimed |
| CN-112979772-B | Magnetic bead with low cleaning residue and preparation method thereof | 江苏集萃分子工程研究院有限公司 | 2022-06-24 | — | — | CN | claimed |
| CN-112979772-A | Magnetic bead with low cleaning residue and preparation method thereof | 江苏集萃分子工程研究院有限公司 | 2021-06-18 | — | — | CN | claimed |
| EP-4739651-A1 | LIPID COMPOUNDS FOR DELIVERY OF THERAPEUTIC AGENTS AND PREPARATION METHOD AND ITS USE THEREOF | Yoltech Therapeutics Co., Ltd (CN) | 2026-05-13 | — | — | EP | disclosed |
| CN-116583303-B | Tripterine conjugates and uses thereof | 瑞阳公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| EP-4711451-A1 | CAS PROTEIN, CORRESPONDING GENE EDITING SYSTEM THEREOF AND USE THEREOF | Yoltech Therapeutics Co., Ltd (CN) | 2026-03-18 | — | — | EP | disclosed |
| CN-121586703-A | Lipid compounds for delivery of therapeutic agents, methods of making and uses thereof | 尧唐(上海)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12503698-B2 | GalNAc derivatives | Janssen Pharmaceuticals, Inc. (US) | 2025-12-23 | — | — | US | disclosed |
| EP-1423136-A1 | POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULATING HALF-LIVES | Epix Medical, Inc. (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1389463-A1 | MEDICINE FOR INHIBITING DRUG ELIMINATION PUMP | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2003013573-A1 | POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULATING HALF-LIVES | EPIX MEDICAL, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| CN-1233237-A | Heteroaryl succinamides and their use as metalloproteinase inhibitors | AGOURON PHARMA (US) | 1999-10-27 | — | — | CN | disclosed |
| US-5254682-A | Treating hypertension, hyperaldosteronism, congestive heart failure; glaucoma | MERCK & CO., INC. (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0518672-A2 | Cyclic renin inhibitors | MERCK & CO. INC. (US) | 1992-12-16 | — | — | EP | disclosed |
| EP-0518675-A2 | Cyclic renin inhibitors | MERCK & CO. INC. (US) | 1992-12-16 | — | — | EP | disclosed |
| EP-0432974-A1 | Cyclic renin inhibitors | MERCK & CO. INC. (US) | 1991-06-19 | — | — | EP | disclosed |
| EP-0431972-A2 | Macrocyclic lactones having renin inhibiting properties | MERCK & CO. INC. (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503698-B2 | GalNAc derivatives | B3GAT3, FUT6, CSGALNACT1 | ALDH1A1 2959/4885MAPK1 3722/4885L3MBTL1 413/4885 |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | ALDH1A1 4264/4885MAPK1 3928/4885L3MBTL1 68/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | ALDH1A1 3566/4885MAPK1 2259/4885L3MBTL1 539/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | ALDH1A1 3438/4885MAPK1 1763/4885L3MBTL1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.